178 Chapter 8 Consistent with previous comparisons of real-life patient cohorts with trial cohorts in SAB9, 84-day mortality was lower in the ARREST and SAFO control arms compared to the Edinburgh cohort. Patients in the Edinburgh and ARREST cohorts predominantly had infection with MSSA (441/458 and 711/758 respectively), and the SAFO trial exclusively recruited people with MSSA bacteraemia. Edinburgh cohort (n=458) ARREST cohort (n=758) SAFO cohort (n=214) P-value Age, years 68 (52-79) 65 (50-76) 65 (54-75) 0.08 Sex, male 292 (53·2) NA1 150 (70·1) 0.11 Acquisition <0.0001 Community acquired 181 (39·5) 485 (64·1) 78 (36·4) Healthcare associated 110 (24·0) 140 (18·5) 52 (24·3) Nosocomial 167 (36·5) 132 (17·4) 84 (39·3) Comorbidities Dementia 44 (9·6) 31 (4·1) 7 (3·3) 0.0002 Chronic kidney disease 35 (7·6) 138 (18·3) 18 (8·4) <0.0001 Liver disease2 57 (12·4) 56 (7·4) 13 (6·1) 0.004 Vascular disease3 121 (26·4) NA 59 (27·6) 0.77 Prosthetic cardiac material4 46 (10·0) NA 16 (7·5) 0.31 Injection drug use 41 (9·0) 83 (11·1) 0 <0.0001 Vital signs Heart rate, beats per minute 98 (85-110) 94 (82-107) NA 0.005 Temperature, °C 38.2 (37.6-38.8) 37.0 (37.0-38.0) 37.3 (36.538.3) <0.0001 Laboratory measurements Haemoglobin, g/L 114 (100-129) 107 (93-122) NA <0.0001 Creatinine, µmol/L 90 (65-138) 80 (61-131) 80 (62-123) 0.05 C-reactive protein, mg/L 156 (69-273) 150 (87-218) NA 0.15 SAB characteristics MRSA 17 (3·7) 47 (6·2) 0 <0.0001 Infective endocarditis 35 (7·6) 40 (5·3) 15 (7·0) 0.21 Other metastatic foci5 99 (21·6) 203 (26·8) 49 (22·9) 0.11 Source of bacteraemia <0.0001 Unknown 163 (35·6) 221 (29·2) 70 (32·7) Intravenous catheter 93 (20·3) 141 (18·6) 68 (31·8)
RkJQdWJsaXNoZXIy MTk4NDMw